Introduction
In the pharmaceutical industry the most exciting aspect of Research & Development is the discovery of a new chemical entity with one or more unique therapeutic properties that are generally recognized and accepted as an advance in safe and effective treatment of disease. The discovery and transformation of this compound into a product which submitted to the authorities can take up to 10 years, costing millions of dollars.
It is the mission of the pharmaceutical development divisions to provide a stable dosage form(s) for evaluation in clinical trials and, ultimately, a competitive market image which can be manufactured at large scale, with reproducible purity and quality and a shelf-life consistent with worldwide environmental conditions. Therefore, analytical testing in R&D laboratories, using stability indicating methods, plays a pivotal role in many of the decisions which lead to the ultimate definition of 'a final product'.
The most time-consuming analyses that occur in analytical R&D laboratories are those associated with stability testing. The minimum requirement is that three batches of the product be manufactured, representative of the commercial manufacturing process, equipment and scale. These are then packaged in each type and size of container which will be used in the market-place. For example, for a tablet dosage form, this might be glass and polyethylene bottles and blisters. All of these are then placed at stability stations, simulating worldwide environmental limits to which the product will be exposed and analytically tested at fixed intervals over a period ofup to three to five years. In addition, the samples are subjected to additional tegting at conditions which are more stressful with the hope that one might project, kinetically, changes which could highlight a stability problem early in the stability protocol. A typical stability protocol for a single dose of a solid dosage form translates into 648 determinations in the first year exclusive of analytical reference standards which must be used in calculations. To give a very different point of view, the use of automation in dissolution testing will be considered next.
Overall, it has b6en found that the gain in productivity is optimal for large volume samples requiring shorter dissolution run times. Therefore, in the author's laboratories, robotics are best suited to dissolution testing of immediate release dosage forms which require h run times and testing of six individual tablets. Automated testing of controlled or sustained release products has its limitations.
(1) All-manual: preparation of all solvents; filling of dissolution pots; sampling at desired intervals; spectrophotometric or chromatographic measurements; calculations.
(2) Semi-automated: In a typical h dissolution test of six tablets (immediate release), using four sample intervals, the data show the following: 
